Medtronic's Percept PC DBS Study for Treatment Resistant Depression Initiated
A new study is investigating the use of Medtronic's Percept PC deep brain stimulation device for treatment resistant depression, focusing on local field potentials.
Phase III
Neurology / Major Depressive Disorder
Status
Initiated
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of Medtronic's study on the Percept PC device for treatment resistant depression (TRD) is significant as it could establish the company as a leader in a niche but critical area of mental health treatment. Success in this trial may not only enhance Medtronic's product offerings but also address a substantial unmet medical need in the TRD segment.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor recruitment progress, LFP data findings, and results from the discontinuation experiment after 6 months.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.